Journal

The Journal of the Japanese Society for Clinical Microbiology

Biblioraphy Information

[Vol.17 No.1 contents]
Japanese / English

download PDF Full Text of PDF (479K)
Article in Japanese

ArticleTitle Comparison of the Percent Time above MIC (%T>MIC) of Meropenem and Imipenem for Pseudomonas aeruginosa by Monte Carlo Simulation
Language J
AuthorList Mariko Wakabayashi, Kenji Tominaga, Kazumi Sakamoto, Harumi Tsurukawa, Saori Maeda, Taku Tamura, Ikurou Abe, Ken Kaito
Affiliation Central Clinical Laboratory, Jikei University Hospital
Publication J.J.C.M.: 17 (1), 8-13, 2007
Received August 25, 2006
Accepted December 18, 2006
Abstract It is very important to pay attention to the pharmacokinetic and pharmacodynamic of antibiotics in the management of infection. We measured the MIC for Pseudomonas aeruginosa of meropenem and imipenem, and analyzed the optimal dose and optimal mode of administration of these drugs by Monte Carlo simulation. Percent time above the MIC (%T>MIC) exposures for 500 mg q12h, 500 mg q8h, and 1,000 mg q12h were simulated for 1,000 subjects, and the target attaining rates of bacteriostatic exposure (%T>MIC: 30%) and bacteriocidal exposure (%T>MIC: 50%) were calculated. The probability of attaining %T>MIC: 30% (TA30%) of two drugs by the 500 mg q12h dosage regimen was high enough (71.9 for meropenem and 59.3 for imipenem), while the probability of attaining %T>MIC: 50% (TA50%) was low (21.5 and 0.1, respectively). The 1,000 mg q12h dosage regimen provided the better TA30% (80.5 and 68.7, respectively) and better TA50% (53.2 and 2.7, respectively). The 500 mg q8h dosage regimen provided the highest TA30% (83.7 and 73.7, respectively) and highest TA50% (68.1 and 41.8, respectively), indicating that the 500 mg q8h dosage regimen would provide the most satisfactory bacterial effect. Monte Carlo simulation is thought to be very beneficial in choosing the antibiotics and its style of administration.
Keywords %T>MIC, Pseudomonas aeruginosa, Monte Carlo simulation, meropenem, imipenem
Copyright © 2002 The Japanese Society for Clinical Microbiology
All rights reserved.